Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kybella and Lasers for NF1 Cutaneous Neurofibromas
NCT04730583Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Neobella in cutaneous neurofibroma (cNF) (3 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 3 months. Started Jun 2021; status: completed.
02
Drugs
Neobella
03
Conditions
cutaneous neurofibroma (cNF)
Beyond the preview
Go deeper on NCT04730583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04730583.